Pharmaceutical projects present a higher level of complexity than many other industrial projects. The combination of Regulatory requirements, qualification,validation, documentary control and quality requirements forces engineering teams to manage each phase with rigorous planning.

However, many of the delays, cost overruns and deviations that occur in the industry do not have their origin in technical problems, but in management errors that could have been avoided. Identifying these recurring failures allows engineers and project managers to anticipate risks and significantly increase the chances of success.

Below we discuss ten of the most common mistakes in pharmaceutical projects and best practices to avoid them.

1. Define unclear or incomplete URS

The User Requirements Specifications (URS) constitute the basis on which the entire project is developed. Poorly defined requirements often lead to later modifications, discrepancies with suppliers, and problems during qualification.

Consequences	Increase in the number of changes. Engineering cost overruns. Delays in execution. Difficulties during validation.
How to avoid it	Involve Production, Quality, Engineering and Maintenance from the beginning. Define functional and regulatory requirements unambiguously. Clearly differentiate mandatory and desirable requirements. Review and formally approve the document before launching tenders.

2. Involving QA too late

In some projects, the Quality department participates only in the final phases. When this happens, requirements that were not initially contemplated usually appear.

Consequences	Repetition of activities. Documentary modifications. Delays in system release.
How to avoid it	· Integrate Quality Assurance (QA) from the conceptual phase to ensure that GMP requirements are incorporated from the design. · The cost of correcting a problem in operation can be dozens of times higher than that of preventing it during design.

3. Underestimate qualification and validation deadlines

One of the most frequent mistakes in pharmaceutical projects is to focus planning on engineering, supply and installation activities, without allocating enough time to the Commissioning, Qualification and Validation (CQV) phases. Since these activities are essential to demonstrate compliance with GMP requirements and authorize the commissioning of equipment and facilities, An incorrect estimate of its duration can significantly compromise project deadlines..

Consequences	Delays in start-up. Conflicts between contractors. Unnecessary pressure on technical teams.
How to avoid it	Plan from the beginning: DQ (Design Qualification). IQ (Installation Qualification). OQ (Operational Qualification). PQ (Performance Qualification). Deviation management. Documentary approvals. Validation should be considered an essential phase of the project and not a closing activity.

4. Not applying structured risk management

Risk management is an essential component of any pharmaceutical project, as it allows you to anticipate problems before they affect scope, schedule or regulatory compliance. However, many organizations continue to adopt a reactive approach, acting only when the incidents have already occurred. In a GMP environment, identifying and evaluating risks from the early phases of the project is key to minimize deviations, optimize resources and guarantee quality of the final result.

Consequences	Increase in incidents. Appearance of critical deviations. Impact on quality and regulatory compliance.
How to avoid it	· Apply recognized methodologies such as FMEA, Risk Assessment GMP, ICH Q9 or Criticality Matrices. · Risk management must remain active throughout the project life cycle.

5. Choose suppliers solely by cost

Supplier selection is a strategic decision in any pharmaceutical project. Although opting for the cheapest offer may seem like a way to reduce costs initially, this decision can lead to quality problems, documentary deficiencies or delays during the qualification and validation phases. In GMP environments, the experience and technical capacity of the supplier are often as important as the price of the offer.

Consequences	Equipment that does not meet specifications. Documentary deficiencies. Delays in FAT and SAT. Increase in hidden costs.
How to avoid it	Additionally evaluate: GMP experience. Technical capacity. History of similar projects. Documentation quality. After-sales support. The total cost of ownership is more relevant than the initial price.

6. Perform superficial FAT and SAT

The Factory Acceptance Test (FAT) and the Site Acceptance Test (SAT) represent fundamental milestones to verify that equipment and systems meet the defined requirements before advancing to the qualification and validation phases. Insufficient planning or superficial execution of these tests can lead to failure. late detection of technical problems, generating delays and increasing project costs.

Consequences	Defects identified too late. Rework in plant. Schedule delays.
How to avoid it	Develop exhaustive protocols. Define clear acceptance criteria. Actively participate in tests. Properly document the results. The more problems detected in FAT, the fewer incidents will arise during qualification.

7. Allow continuous scope changes

Inadequate management of scope changes, known as scope creep, is one of the main causes of deviations in pharmaceutical projects. As the project progresses, new needs or requirements may arise; However, incorporating changes without prior evaluation can affect the budget, the schedule and the fulfillment of the established objectives.

Consequences	Increase in costs. Loss of project control. Cumulative delays.
How to avoid it	Implement a formal change management system that includes: Technical justification. Economic evaluation. Regulatory impact. Approval by interested parties. Not all changes must be accepted.

8. Neglecting document management

Documentation is a critical element in any pharmaceutical project, as it provides the necessary evidence to demonstrate that the equipment, systems and facilities meet the defined requirements and applicable regulatory demands. Poor document management can compromise project traceability, delay qualification activities and create difficulties during audits and inspections.

Consequences	Observations in audits. Delays in release. Traceability problems.
How to avoid it	Control from the beginning: Validation Master Plan. Functional specifications. As-built plans. Material certificates. Protocolos DQ/IQ/OQ/PQ. Manuals and procedures. Document collection should not be left until the end of the project.

9. Lack of communication between departments

Pharmaceutical projects require the collaboration of multiple departments, each with specific responsibilities, priorities and objectives. When communication between Engineering, Production, QA, Validation and other teams is not effective, misunderstandings, delays in decision making and difficulties coordinating critical activities can arise. Clear and structured communication is essential to ensure the progress of the project and avoid unnecessary deviations.

Consequences	Contradictory decisions. Duplication of efforts. Delays in resolving incidents.
How to avoid it	Establish: Periodic meetings. Responsibility matrices. Progress reports. Open stock records. Effective communication significantly reduces coordination problems.

10. Not capturing lessons learned

Once a project is completed, it is common for teams to focus their efforts on the transfer to operations and support activities, leaving the compilation of acquired experiences in the background. However, document successes, challenges and opportunities for improvement It is essential to avoid repetition of errors and strengthen the organization's ability to manage future projects more efficiently.

Consequences	Repetition of errors. Loss of organizational knowledge. Lower efficiency in future projects.
How to avoid it	Conduct a final review that includes: Main successes. Problems found. Cost and deadline deviations. Recommendations for future projects. Lessons learned are one of the most valuable tools for continuous improvement.

Conclusion

Successful pharmaceutical projects depend not only on solid engineering, but also on effective management that integrates quality, regulatory compliance, risk management and multidisciplinary coordination.

Errors such as poor definition of requirements, late involvement of Quality, lack of qualification planning or inadequate change management are often behind many delays and cost overruns. On the contrary, organizations that incorporate these good practices from the initial phases achieve more predictable, efficient and aligned projects with GMP requirements.

In an increasingly regulated and competitive environment, learning from the most frequent mistakes can make the difference between a problematic implementation and a project delivered successfully, within the deadline, budget and quality standards required by the pharmaceutical industry.

Want to avoid these mistakes on your next project? Contact our team from experts in pharmaceutical engineering, qualification and validation to discover how we can help you ensure the success of your GMP facilities.